Maharashtra FDA Calls for Tightening Price Gaps in Hospital Consumables

In a move that has raised eyebrows across the state’s health circles, Maharashtra’s Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has formally written to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA). His letter, dated September 2026, isn’t just a routine report – it’s a pointed request for new guidelines that would cap the difference between what hospitals actually pay for consumables and the maximum retail price (MRP) printed on the packaging.

“The most expensive part of a hospital bill may never touch the hospital at all,” Mundhe warned during a brief press briefing. “A patient admitted for care has no way of knowing whether the price on a medical consumable reflects its actual cost or a markup fixed long before it ever reached the ward.” In other words, the price tags we see on syringes, IV sets and catheters could be more about profit than the real cost of production.

His concerns stem from a recent survey of hospital consumables conducted across Maharashtra. The numbers are staggering: an IV infusion set bought at a trade price of just ₹11.05 was bearing an MRP of ₹325 – a markup of almost 2,900 per cent. A simple syringe, procured for ₹6.75, carried an MRP of ₹57.20, while a catheter that cost ₹29.41 in the supply chain was listed at ₹310. Those gaps, Mundhe argued, are not merely accounting quirks; they are a public‑health issue that erodes trust and makes care unaffordable.

He emphasized that the problem is two‑fold. First, there is a clear need to close the pricing gap itself – to ensure that the marked‑up price does not wildly exceed the procurement cost. Second, and perhaps more importantly, patients need transparency. When a hospital’s purchase decisions are made behind closed doors, patients cannot compare prices, shop for alternatives or even question the bill they receive.

On X (formerly Twitter), Mundhe added a personal note: “These are not elective purchases. A patient can’t walk around the pharmacy and say ‘I’ll get a cheaper syringe elsewhere.’ The system should protect them, not leave them guessing.” He urged the NPPA to draft a set of enforceable norms that would define a permissible margin between trade price and MRP, and to monitor compliance through regular audits.

While the FDA’s mandate traditionally focuses on safety and quality, Mundhe’s letter signals a broader shift toward price regulation in the medical sector. If the NPPA adopts his recommendations, hospitals may have to disclose procurement costs, and manufacturers could face stricter penalties for inflating MRPs without justification.

For patients and their families, the hope is simple: a clearer, fairer price structure that reflects actual costs rather than opaque markups. For the industry, it could mean a period of adjustment – but perhaps one that ultimately builds confidence in the health‑care system.